Immunome, Inc. (NASDAQ:IMNM) Shares Sold by Marshall Wace LLP

Marshall Wace LLP reduced its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 17.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,216,182 shares of the company's stock after selling 251,228 shares during the period. Marshall Wace LLP owned about 1.52% of Immunome worth $12,916,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in shares of Immunome by 6.6% in the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock worth $359,000 after buying an additional 1,520 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Immunome by 11.7% in the 4th quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company's stock valued at $202,000 after purchasing an additional 2,000 shares during the period. Intech Investment Management LLC grew its position in shares of Immunome by 26.5% during the 4th quarter. Intech Investment Management LLC now owns 18,961 shares of the company's stock valued at $201,000 after acquiring an additional 3,974 shares during the period. Wellington Management Group LLP increased its stake in shares of Immunome by 3.5% in the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company's stock valued at $1,546,000 after purchasing an additional 4,874 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Immunome during the fourth quarter worth approximately $75,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Guggenheim decreased their target price on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Lake Street Capital began coverage on shares of Immunome in a research report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price target for the company. Lifesci Capital began coverage on Immunome in a research note on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price objective for the company. Stephens reiterated an "overweight" rating and set a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th. Finally, Wedbush restated an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $25.14.

Insider Buying and Selling

In other news, CTO Philip Tsai bought 12,300 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was bought at an average cost of $8.42 per share, for a total transaction of $103,566.00. Following the acquisition, the chief technology officer now directly owns 33,300 shares of the company's stock, valued at $280,386. The trade was a 58.57 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jean Jacques Bienaime purchased 7,000 shares of the business's stock in a transaction on Monday, March 24th. The shares were acquired at an average price of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the purchase, the director now directly owns 23,615 shares of the company's stock, valued at approximately $193,879.15. This trade represents a 42.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 306,400 shares of company stock valued at $2,322,995. 8.60% of the stock is currently owned by insiders.

Immunome Trading Down 1.4 %

Immunome stock traded down $0.12 during midday trading on Friday, hitting $8.40. 1,635,419 shares of the stock were exchanged, compared to its average volume of 1,089,464. The stock's 50-day simple moving average is $8.03 and its 200 day simple moving average is $10.26. Immunome, Inc. has a fifty-two week low of $5.15 and a fifty-two week high of $16.81. The stock has a market capitalization of $730.39 million, a price-to-earnings ratio of -1.04 and a beta of 2.05.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.74 million during the quarter, compared to analysts' expectations of $3.07 million. Equities analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.